WHO Expert Committee on Drug Dependence: Difference between revisions
| Line 26: | Line 26: | ||
==Meetings== |
==Meetings== |
||
Due to the large amounts of meetings in the ECDD, this list will only go as far to the 45th Committee Meeting. |
|||
'''46th Expert Committee on Drug Dependence Meeting'''<ref>{{cite web |title=46th Expert Committee on Drug Dependence |url=https://www.who.int/groups/who-expert-committee-on-drug-dependence/46th-ecdd-documents |publisher=WHO}}</ref> |
'''46th Expert Committee on Drug Dependence Meeting'''<ref>{{cite web |title=46th Expert Committee on Drug Dependence documents |url=https://www.who.int/groups/who-expert-committee-on-drug-dependence/46th-ecdd-documents |website=Expert Committee on Drug Dependence |publisher=WHO (ECDD)}}</ref> |
||
was held on 16th October 2023, and reviewed 8 different drugs, such as: Benzodiazepines such as [[Bromazolam]] and [[Flubromazepam]], Novel synthetic [[Opioid|opioids]] such as [[Butonitazene]], [[Substituted cathinone|Cathinones]]/[[Stimulant|stimulants]] such as [[3-Chloromethcathinone|3-CMC]] and [[Dipentylone]], Dissociative-type substances such as [[2-Fluorodeschloroketamine|2-fluorodeschloroketamine]] as well as medicines such as [[Nitrous oxide (medication)|Nitrous Oxide (medication)]] and [[Carisoprodol]]. |
|||
'''45th Expert Committee on Drug Dependence Meeting |
'''45th Expert Committee on Drug Dependence Meeting'''<ref>{{cite web |title=Expert Committee on Drug Dependence |url=https://www.who.int/groups/who-expert-committee-on-drug-dependence/45th-ecdd-documents |website=45th Expert Committee on Drug Dependence documents |publisher=WHO (ECDD)}}</ref> |
||
45th Expert Committee on Drug Dependence Meeting was held on the 10th of October 2022, and reviewed 9 different drugs such as: [[Cannabinoid|Cannabinoids]] such as [[ADB-BUTINACA]], |
45th Expert Committee on Drug Dependence Meeting was held on the 10th of October 2022, and reviewed 9 different drugs such as: [[Cannabinoid|Cannabinoids]] such as [[ADB-BUTINACA]], |
||
[[Benzodiazepine|Benzodiazepines]] such as [[Adinazolam]] and [[Bromazolam]], [[Opioid|syntetic opioids]] such as [[Protonitazene]], [[Etodesnitazene|Etodesnitazene]], [[etonitazene|N-pyrrolidino etonitazene)]] and [[2-Methyl-AP-237]], Stimulants such as: [[Alpha-Pyrrolidinohexiophenone|alpha-PiHP]] and 3[[3-Methylmethcathinone|-Methylmethcathinone (3-MMC)]] and medicines such as [[Zopiclone]]. |
[[Benzodiazepine|Benzodiazepines]] such as [[Adinazolam]] and [[Bromazolam]], [[Opioid|syntetic opioids]] such as [[Protonitazene]], [[Etodesnitazene|Etodesnitazene]], [[etonitazene|N-pyrrolidino etonitazene)]] and [[2-Methyl-AP-237]], Stimulants such as: [[Alpha-Pyrrolidinohexiophenone|alpha-PiHP]] and 3[[3-Methylmethcathinone|-Methylmethcathinone (3-MMC)]] and medicines such as [[Zopiclone]]. |
||
Revision as of 14:42, 11 December 2023
| Parent institution | World Health Organization |
|---|---|
| Established | 1948 |
| Mission | Conducting the medical and scientific evaluation of drugs |
| Members | 11 |
| Website | ECDD Website |
The WHO Expert Committee on Drug Dependence (ECDD) is a committee within the World Health Organisation (WHO) that consists of a chosen group of independent experts within the field of pharmacology. This committee meets once a year in order to evaluate the effects of psychotic substances towards the public and the properties that cause the addictions, and considering the possible medical or therapeutic benefits and applications.[1]
Committee Members
This list is updated alongside the 2023 46th ECDD Committee Member List:[2]
- Prof. Patrick Beardsley
- Dr. Wim Best
- Dr. Sandra Comer
- Dr. Ifeoma Toyin Ekwere
- Dr. Simon Elliott
- Prof. Raka Jain
- Dr Pamela Kaduri
- Dr. Junichi Kitanaka
- Dr. Antonio Pascale Prieto
- Dr. Afarin Rahimi-Movaghar
- Prof. Jason White
- Suti Nudmamud Thanoi
Meetings
Due to the large amounts of meetings in the ECDD, this list will only go as far to the 45th Committee Meeting.
46th Expert Committee on Drug Dependence Meeting[3] was held on 16th October 2023, and reviewed 8 different drugs, such as: Benzodiazepines such as Bromazolam and Flubromazepam, Novel synthetic opioids such as Butonitazene, Cathinones/stimulants such as 3-CMC and Dipentylone, Dissociative-type substances such as 2-fluorodeschloroketamine as well as medicines such as Nitrous Oxide (medication) and Carisoprodol.
45th Expert Committee on Drug Dependence Meeting[4] 45th Expert Committee on Drug Dependence Meeting was held on the 10th of October 2022, and reviewed 9 different drugs such as: Cannabinoids such as ADB-BUTINACA, Benzodiazepines such as Adinazolam and Bromazolam, syntetic opioids such as Protonitazene, Etodesnitazene, N-pyrrolidino etonitazene) and 2-Methyl-AP-237, Stimulants such as: alpha-PiHP and 3-Methylmethcathinone (3-MMC) and medicines such as Zopiclone.
Substances Under Watchlist
The ECDD currently have 25 drugs under their watchlist as of 2023[5], split into 7 different cateogories: Psychoactive Medicines, Tryptamines, Opioids, Synthetic cathinones, Synthetic Cannabinoid Receptor Agonists, Benzodiazepines and Amphetamine-type stimulants.
See also
References
- ^ "46th ECDD Committee Member Biographies" (PDF). WHO.
- ^ "The WHO Expert Committee on Drug Dependence (ECDD)". WHO. 2023.
- ^ "46th Expert Committee on Drug Dependence documents". Expert Committee on Drug Dependence. WHO (ECDD).
- ^ "Expert Committee on Drug Dependence". 45th Expert Committee on Drug Dependence documents. WHO (ECDD).
- ^ "LIST OF SUBSTANCES UNDER SURVEILLANCE 2023" (PDF). WHO ECDD.